Search Tag: dapagliflozin

Cardiology Management

#ESCCongress: Findings from DAPA-CKD Trial

2020 30 Aug

The main results of the DAPA-CK trial were presented today at ESC Congress 2020. Findings showed that dapagliflozin reduces the risk of kidney failure, death from cardiovascular causes or heart failure hospitalisation and all-cause mortality in chronic kidney disease patients with or without type 2 diabetes. The goal of the DAPA-CKD trial was to... Read more

Cardiology Management

#ESCCongress: DAPA-HF Trial - Reduction in Cardiovascular Death, Hospitalisation

2019 01 Sep

The DAPA-HF study findings were presented today by Dr. John McMurray at the ESC Congress in Paris.  DAPA-HF is an international, multi-centre, parallel-group, randomised, double-blind trial in patients with heart failure and reduced ejection fraction (LVEF = 40%), with and without type-2 diabetes, designed to evaluate the effect of dapagliflozin,... Read more

Cardiology Management

#ESCCongress Preview: DAPA-HF Trial

2019 29 Aug

The DAPA-HF trial is the first heart failure outcomes trial with dapagliflozin, an SGLT2 inhibitor, in patients with and without Type-2 diabetes. Findings from the trial will be presented at the ESC Congress next week.  DAPA-HF is an international, multi-centre, parallel-group, randomised, double-blind trial in patients with heart failure... Read more